The benzodiazepine hangover: Next-day residual effects on driving performance.
|
|
- Conrad Moore
- 6 years ago
- Views:
Transcription
1 The benzodiazepine hangover: Next-day residual effects on driving performance. Stefanie Leung, Faculty of Medicine, The University of Sydney Nicholas Lintzeris, Drug and Alcohol Services, South Eastern Sydney Local Health District Michael Lenne, Monash University Accident Research Centre, Monash University Ian Faulks, Safety and Policy Analysis International Raimondo Bruno, Department of Psychology, University of Tasmania Paul Haber, Drug Health Services, South Local Health District Abstract Context Benzodiazepines (BZDs) are implicated in a considerable proportion of road crashes in Australia (behind only alcohol and cannabis respectively). In fact, BZD hypnotics are the pharmaceutical drug most commonly detected in driver fatalities and serious injuries in Australia. Based on epidemiological estimates, the road safety burden from BZDs is almost on par with the road safety burden relating to all illicit drugs combined. Objectives A review of reported patterns of BZD use, epidemiological studies of BZDs and crash risk, and laboratory studies of psychomotor and cognitive effects of BZDs was conducted. Key Outcomes BZD hypnotics provide clinically desirable effects (e.g. sedation and reduced alertness) at night for insomniacs. However, these same effects become adverse if experienced during the day. Ideally, a hypnotic should facilitate sleep at night (the typical time taken) but be free from residual sedative effects the following morning. Even relatively subtle residual effects may have serious consequences for daily activities and potentially devastating effects on road safety. Aside from the acute impairing effects of BZDs that may impair driving performance, there is a need to consider issues associated with longer-term use. BZDs are frequently used outside clinical guidelines (i.e. long-term), despite the absence of clinical evidence to inform this practice. It is now widely accepted that, even at normal therapeutic doses, BZDs have the ability to cause both physiological and pharmacological dependence. This is evidenced by the onset of withdrawal symptoms when the drugs are discontinued. Nevertheless, there is still considerable debate about whether BZDs effect any long-term impairment on sleep architecture and cognition. Discussion and conclusions This paper highlights gaps in the current knowledge relating to residual BZD effects on driving and cognitive performance with chronic use, and suggests approaches for future research to inform appropriate management of and advice relating to BZD use. 1
2 Introduction Benzodiazepine (BDZ) hypnotics are primarily indicated to treat sleep-related disorders, a condition that is estimated to be prevalent in 10-40% of adults (Mai & Buysse, 2008). For sufferers of insomnia, the medications used to treat the condition, as well as the condition itself, have both been associated with compromised fitness-to-drive. In fact, BZDs are the prescription drug most commonly found in injured (~14%) and fatally-injured (~5%) drivers (Drummer et al., 2003; Griggs et al., 2007). They are also one of the most commonly prescribed psychoactive medicines in Australia, with script volumes remaining relatively constant over the last 10 years (Figure 1). Figure 1: Pharmaceutical benefits scheme (PBS) script volumes for benzodiazepines from 2003 to 2012 (data sourced from Medicare Australia, 2013). Residual impairment of driving performance after hypnotic BZD use BZD hypnotics should facilitate sleep at night (the typical time when taken), with resolution of any sedative effects by the following morning. However, data from reported patterns of use, and epidemiological studies of crash risk and laboratory studies, together point to there being residual effects of the medication (Rapoport & Banina, 2007). This has implications for daytime functioning and alertness, and could result in impairment of cognitive and psychomotor skills, such as those required to safely drive a car. The strength of the residual effect is believed to be dependent on the type, dose, time since administration and frequency of dosing of the BZD, although this is not exclusively the case (Vermeeren, 2004). Hypnotics with short half-lives have also been shown to produce residual effects. As such, there is currently no clarity about which BZDs produce residual effects, how long these effects persist, and to what extent the effects influence cognitive functioning and driving skills. Epidemiological studies have indicated that there is an increased risk of crash involvement the morning after administration of a BZD hypnotic, although the strength of this association 2
3 remains unsubstantiated due to conflicting evidence (Rapoport et al., 2009; Smink, Egberts, Lusthof, Uges, & de Gier, 2010; Vermeeren, 2004). This is, in part, due to other consumer factors (such as age, comorbid medical or psychiatric disorders, other medications) rather than the BZDs themselves. As such, culpability is yet to be confirmed. A number of laboratory and driving simulator studies have demonstrated the potential for residual impairment of tracking ability, visual discrimination and reaction time, up to 11 hours after night-time administration of a BZD (Seppala, Korttila, Hakkinen, & Linnoila, 1976; Verster, Veldhuijzen, & Volkerts, 2004; Willumeit, Ott, & Neubert, 1984). This phenomenon has typically been more prominent with long-acting BZDs (Hindmarch & Subhan, 1983; Iudice et al., 2002), although exceptions have been reported. Flunitrazepam (2mg) and lorazepam (1mg) are two examples of intermediate-acting BZDs that have demonstrated residual effects on on-road car handling, up to 17 hours post-dose, in insomniacs and anxious patients respectively (Hindmarch & Gudgeon, 1980; Verster, Veldhuijzen, Patat, Olivier, & Volkerts, 2006). Lorazepam has also been shown to impair on-road driving performance (tracking ability) in both anxious patients and healthy volunteers treated with 2mg lorazepam twice daily for 7 days (Verster et al., 2004; Verster, Veldhuijzen, & Volkerts, 2005). Long-term BZD use and cognitive impairment A question of tolerance? Estimates from the National Health Survey revealed that over 200,000 Australians had used BZDs to treat a sleep disorder (i.e. BZD hypnotics) in the 2 weeks prior to being surveyed, with approximately 30% of those having used the medications on more than three occasions per week for six months or longer (Australian Bureau of Statistics, 2009). There are very few, if any, accepted medical indications for such long-term use. Despite this, BZDs are commonly used outside therapeutic guidelines (Mant & Walsh, 1997). A recent thesis by Hansen (2012) demonstrated a strong relationship between sedative prescriptions and risk of motor vehicle crash (hazard ratio = 2.23, n = 676,694), with the highest risk group being those who had days of continuous prescription fills (Hansen, 2012). This long-term use has implications for the safe and effective conduct of complex daytime activities such as driving. However, to date, only two experimental driving studies have endeavoured to address the question of driving impairment after chronic BZD hypnotic use (>3 months for at least 4 nights per week) the morning after use, and these were done in a population comprised of older drivers (T.R.M Leufkens, Ramaekers, de Weerd, Riedel, & Vermeeren, 2011; Tim R. M. Leufkens, 2009). The placebo-controlled crossover study found significant residual impairment of zopiclone (7.5mg) on highway driving in unmedicated insomniacs, chronic users of hypnotics and normal sleepers, while the parallel design cohort study revealed no significant differences between highway driving performances of unmedicated insomniacs, chronic users of hypnotics and normal sleepers. Directions for future experimental research Despite the existence of epidemiological research relating the use of BZDs with an increased risk of road crashes (Orriols et al., 2011), limited experimental evidence exists to confirm a causative role, particularly when considering chronic use and/or residual effects. The research that does exist remains inconclusive. There are a number of key limitations that could account for the disparity in previous experimental findings. Namely, these studies either utilised only laboratory-based psychomotor tests (as opposed to on-road or driving simulator tests), or adopted an acute dosing regime (e.g. single dosing or repeated dosing up to a maximum of 17 days), and in most cases examined the phenomenon in healthy volunteers rather than a patient population (e.g. insomnia patients) (Rapoport et al., 2009; Vermeeren, 2004). Two studies by Leufkens and colleagues are the only exceptions. Both these on-road 3
4 studies investigated the chronic and residual effects of benzodiazepine use in a patient population, compared to age-matched healthy controls and unmedicated insomniac controls. Only one found significant differences in driver performance, and that was after zopiclone administration. It should be noted, however, that the age range of the participants in both studies was 52 to 73 years, with the mean age of over 60 years in each experimental group. Age is of particular importance to both driving and cognitive performance, particularly when considering that cognitive degradation increases with increasing age and the proclivity of certain age groups to be involved in road crashes (age <25 and >65 being at highest risk). Although the prevalence of chronic benzodiazepine use does peak in the elderly, use/misuse remains considerable in the younger populations and has been shown to increase steadily in those aged in their mid-20s onwards (Hollingworth & Siskind, 2010). Despite this, there is continued neglect in the experimental literature of the effects of benzodiazepine use in younger age groups. Conclusion The evidence base regarding benzodiazepine-induced residual driving impairment is currently tenuous as described above, and hence clear guidelines in relation to driving while taking these medications have not been developed. Despite a number of epidemiological studies relating the use of benzodiazepine hypnotics with road crashes, limited experimental data exists to confirm a causative role. Indeed, the absence of a systematic assessment of the impairing effects in patients suffering from insomnia compared to a control sample, has recently been identified as a major gap in our understanding (Rapoport et al., 2009). As such, further high impact experimental research is required to quantify the impairing effects of BZDs on driving and cognitive task performances the next day following night-time use. The outcomes of such research will subsequently inform appropriate management of and advice relating to BZD use and the implications for safe driving. References Australian Bureau of Statistics. (2009). National Health Survey: Summary of Results, (Reissue), Australia. (Cat. no ). Canberra: Australian Government Publishing Service. Drummer, Olaf H., Gerostamoulos, Jim, Batziris, Helen, Chu, Mark, Caplehorn, John R. M., Robertson, Michael D., & Swann, Philip. (2003). The incidence of drugs in drivers killed in Australian road traffic crashes. Forensic Science International, 134(2-3), Griggs, W, Caldicott, D, Pfeiffer, J, Edwards, N, Pearce, A, & Davey, M. (2007). The impact of drugs on road crashes, assaults and other trauma a prospective trauma toxicology study Monograph Series No. 20: National Drug Law Enforcement Research Fund Hansen, R.N. (2012). Investigating the Association Between Sedative Hypnotic Prescription Exposures and Motor Vehicle Crashes. (PhD), University of Washington. Hindmarch, I., & Gudgeon, A. C. (1980). The effects of clobazam and lorazepam on aspects of psychomotor performance and car handling ability. British Journal of Clinical Pharmacology, 10(2), Hindmarch, I., & Subhan, Z. (1983). The effects of midazolam in conjunction with alcohol on sleep, psychomotor performance and car driving ability. International Journal of Clinical Pharmacology Research, 3(5), Hollingworth, S. A., & Siskind, D. J. (2010). Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiology and Drug Safety, 19(3), doi: /pds
5 Iudice, A., Bonanni, E., Maestri, M., Nucciarone, B., Brotini, S., Manca, L.,... Murri, L. (2002). Lormetazepam effects on daytime vigilance, psychomotor performance and simulated driving in young adult healthy volunteers. International Journal of Clinical Pharmacology & Therapeutics, 40(7), Leufkens, T.R.M, Ramaekers, J.G., de Weerd, A.W., Riedel, W.J., & Vermeeren, A. (2011). Driving performance of chronic users of hypnotics and unmedicated insomnia patients. In J. G. Ramaekers (Ed.), Effects of medicinal drugs on actual and simulated driving: Maastricht University, The Netherlands. Leufkens, Tim R. M. (2009). Hypnotics and anxiolytics: Field and laboratory measures of drug safety in driving performance and cognitive functions. (PhD), Maastricht University, The Netherlands. Mai, E., & Buysse, D. J. (2008). Insomnia: Prevalence, Impact, Pathogenesis, Differential Diagnosis, and Evaluation. Sleep Med Clin, 3(2), doi: /j.jsmc Mant, Andrea, & Walsh, Raoul A. (1997). Reducing benzodiazepine use. Drug and Alcohol Review, 16(1), doi: / Orriols, L., Philip, P., Moore, N., Castot, A., Gadegbeku, B., Delorme, B.,... Lagarde, E. (2011). Benzodiazepine-Like Hypnotics and the Associated Risk of Road Traffic Accidents. Clinical Pharmacology & Therapeutics, 89(4), Rapoport, M. J., & Banina, M. C. (2007). Impact of psychotropic medications on simulated driving - A critical review. CNS Drugs, 21(6), Rapoport, M. J., Lanctot, K. L., Streiner, D. L., Bedard, M., Vingilis, E., Murray, B.,... Herrmann, N. (2009). Benzodiazepine Use and Driving: A Meta-Analysis. Journal of Clinical Psychiatry, 70(5), Seppala, K., Korttila, K., Hakkinen, S., & Linnoila, M. (1976). Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam. British Journal of Clinical Pharmacology, 3(5), Smink, B. E., Egberts, A. C. G., Lusthof, K. J., Uges, D. R. A., & de Gier, J. I. (2010). The Relationship between Benzodiazepine Use and Traffic Accidents A Systematic Literature Review. CNS Drugs, 24(8), Vermeeren, A. (2004). Residual effects of hypnotics - Epidemiology and clinical implications. CNS Drugs, 18(5), Verster, Joris C., Veldhuijzen, Dieuwke S., Patat, Alain, Olivier, Berend, & Volkerts, Edmund R. (2006). Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Current Drug Safety, 1(1), Verster, Joris C., Veldhuijzen, Dieuwke S., & Volkerts, Edmund R. (2004). Residual effects of sleep medication on driving ability. Sleep Medicine Reviews, 8(4), Verster, Joris C., Veldhuijzen, Dieuwke S., & Volkerts, Edmund R. (2005). Is it Safe to Drive a Car when Treated with Anxiolytics? Evidence from onthe- Road Driving Studies During Normal Traffic. Current Psychiatry Reviews, 1, Willumeit, H. P., Ott, H., & Neubert, W. (1984). Simulated car driving as a useful technique for the determination of residual effects and alcohol interaction after short- and longacting benzodiazepines. Psychopharmacology - Supplementum, 1,
INVOLVEMENT OF DRUGS IN ACCIDENT CAUSATION
INVOLVEMENT OF DRUGS IN ACCIDENT CAUSATION Jim GEROSTAMOULOS, Helen BATZIRIS, Olaf H. DRUMMER Victorian Institute of Forensic Medicine and Department of Forensic Medicine, Monash University, Southbank,
More informationRisk of Involvement of Medicinal Drugs in Traffic Crashes
Risk of Involvement of Medicinal Drugs in Traffic Crashes OLAF H.DRUMMER Victorian Institute of Forensic Medicine & Department of Forensic Medicine, Monash University, 57-83 Kavanagh Street, Southbank,
More informationReducing cannabis-impaired driving: Is there sufficient evidence for drug-testing of drivers?
Reducing cannabis-impaired driving: Is there sufficient evidence for drug-testing of drivers? Author Hall, Wayne, Homel, Ross Published 2007 Journal Title Addiction DOI https://doi.org/10.1111/j.1360-0443.2007.02042.x
More informationDrugs, Driving DQG 7UDI½F 6DIHW\ (GLWHG E\ - & 9HUVWHU 6 5 3DQGL 3HUXPDO - * 5DPDHNHUV DQG - - GH *LHU %LUNKlXVHU %DVHO À %RVWRQ À %HUOLQ
Drugs, Driving Contents Contents V Dedication... IX Credits and acknowledgements... XI List of contributors... XIII Preface... XIX... 1 Henry J. Moller Worldwide trends in alcohol and drug impaired driving...
More informationResidual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study
Psychopharmacology (2014) 231:2785 2798 DOI 10.1007/s00213-014-3447-z ORIGINAL INVESTIGATION Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls:
More informationHypnotics drugs residual effects on monotonous simulated driving in elderly drivers
Hypnotics drugs residual effects on monotonous simulated driving in elderly drivers ML Bocca 1-2, S Marie 2, C. Berthelon 3*, A. Coquerel 2, V. Lelong-Boulouard 2, M. Moessinger 4, P. Denise 2 1 : Paris
More informationReview of Drug Impaired Driving Legislation (Victoria Dec 2000) and New Random Drug Driving Legislation Based on Oral Fluid Testing
Review of Drug Impaired Driving Legislation (Victoria Dec 2000) and New Random Drug Driving Legislation Based on Oral Fluid Testing P D Swann MC Boorman JJ Potter VicRoads Road Safety Department 60 Denmark
More informationOn-the-road driving tests and neurocognitive tests for measuring the effects of cannabis on driving
On-the-road driving tests and neurocognitive tests for measuring the effects of cannabis on driving JG Ramaekers Dept Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht
More informationImpairment and Driving Assessments of Drivers Given Amphetamines, Cannabis and Benzodiazepines and Oral Fluid Testing Results.
Impairment and Driving Assessments of Drivers Given Amphetamines, Cannabis and Benzodiazepines and Oral Fluid Testing Results. PD Swann MC Boorman K Papafotiou Drugs and Driving Research Unit, School of
More informationSupplemental Digital Content
CNS Drugs The Relationship between Benzodiazepine Use and Traffic Accidents A Systematic Literature Review Beitske E. Smink, et al. Supplemental Digital Content This Supplemental Digital Content contains
More information1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)
Dr. Paul A. Farnan farnan@mail.ubc.ca HealthQuest Occupational Health Corporation Alliance Medical Monitoring I have no financial interests or affiliation with any pharmaceutical industry or manufacturer
More informationIs it Safe to Drive a Car when Treated with Anxiolytics? Evidence from onthe-road Driving Studies During Normal Traffic
Current Psychiatry Reviews, 2005, 1, 215-225 215 Is it Safe to Drive a Car when Treated with Anxiolytics? Evidence from onthe-road Driving Studies During Normal Traffic Joris C. Verster*, Dieuwke S. Veldhuijzen
More informationMARIJUANA USE AMONG DRIVERS IN CANADA,
T R A F F I C I N J U R Y R E S E A R C H F O U N D A T I O N MARIJUANA USE AMONG DRIVERS IN CANADA, 2000-2014 Traffic Injury Research Foundation, December 2017 Introduction Public concern about drug-impaired
More informationdrug trends bulletin Driving behaviours among people who inject drugs in South Australia, Key findings december 2011 ISSN
drug trends december 2011 bulletin Authors: Rachel Sutherland and Lucy Burns, National Drug and Alcohol Research Centre, University of New South Wales Funded by the Australian Government Department of
More informationMarijuana use and car crash injury
RESEARCH REPORT Blackwell Science, LtdOxford, UKADDAddiction0965-2140 2005 Society for the Study of Addiction 100 Original Article Marijuana use and car crash injury Stephanie Blows et al. Marijuana use
More informationDrug Profiles of Apprehended Drivers in Victoria
Drug Profiles of Apprehended Drivers in Victoria J Gerostamoulos, P McCaffrey, O H. Drummer and M Odell*. Victorian Institute of Forensic Medicine, Department of Forensic Medicine, Monash University, 57-83
More informationDrugs and Driving: Detection and Deterrence
Drugs and Driving: Detection and Deterrence Advisory Group on Drugs in Traffic Report prepared by : Douglas J. Beirness, Ph.D., Barry K. Logan, Ph.D., Philip Swann, Ph.D. Key Messages Drugs are as serious
More informationCannabis, Cannabinoids and Driving
Cannabis, Cannabinoids and Driving What is the affect of cannabinoids on driving. The FDA has the best answer. It s apparent that the FDA does not believe that the mere presence of cannabinoids or their
More informationDriving and Pain. Guidance for Faculty of Pain Medicine Members
Driving and Pain Guidance for Faculty of Pain Medicine Members Introduction Road traffic accidents remain a significant public health problem in the UK. In 2016 there were over 180,000 casualties resulting
More informationConcurrent Use of Benzodiazepines and Antidepressants and the Risk of Motor Vehicle Accident in Older Drivers: A Nested Case Control Study
Neurol Ther (2015) 4:39 51 DOI 10.1007/s40120-015-0026-0 ORIGINAL RESEARCH Concurrent Use of Benzodiazepines and Antidepressants and the Risk of Motor Vehicle Accident in Older Drivers: A Nested Case Control
More informationAlcohol and drugs among motorcycle riders compared with car and van drivers killed in road crashes in Norway during
Alcohol and drugs among motorcycle riders compared with car and van drivers killed in road crashes in Norway during 2001-2010 Asbjørg S. Christophersen and Hallvard Gjerde Norwegian Institute of Public
More informationEffects of Central Nervous System Depressants on Driving
Effects of Central Nervous System Depressants on Driving What is the Drug-Impaired Driving Learning Centre (DIDLC)? The Drug Impaired Driving Learning Centre (DIDLC) is a fully bilingual, web-based educational
More informationEffects of Cannabis on Driving
Effects of Cannabis on Driving What is the Drug-Impaired Driving Learning Centre (DIDLC)? The Drug Impaired Driving Learning Centre (DIDLC) is a fully bilingual, web-based educational resource that was
More informationCannabis and Driving: A Scientific and Rational Review (2011 Update)
Cannabis and Driving: A Scientific and Rational Review (2011 Update) Paul Armentano Deputy Director NORML NORML Foundation September 12, 2011-1 Policy debates regarding marijuana law reform invariably
More informationClinical Impairment of Benzodiazepines Relation between Benzodiazepine Concentrations and Impairment in Apprehended Drivers.
Clinical Impairment of Benzodiazepines Relation between Benzodiazepine Concentrations and Impairment in Apprehended Drivers. 1 J.G. Bramness, 2 S. Skurtveit, and 1 J. Mørland 1 National Institute of Forensic
More informationSYNOPSIS INTRODUCTION
THE EFFECTS OF THE (SUB)CHRONIC ADMINISTRATION OF AN ANTIHISTAMINE AND MEBHYDROLIN ON REAL CAR DRIVING AND PSYCHOMOTOR PERFORMANCE OF PATIENTS AND HEALTHY VOLUNTEERS * * * * J. J. de Gier, ; J. A. M. Van
More informationBenzodiazepines: risks, benefits or dependence
Benzodiazepines: risks, benefits or dependence A re-evaluation Council Report CR 59 January 1997 Royal College of Psychiatrists, London Due for review: January 2002 1 Contents A College Statement 3 Benefits
More informationBenzodiazepines. Benzodiazepines
: History 1950s - Invented by Swiss chemists who identified its sedative effects 1950s 60s - Chlordiazepoxide (Librium) marketed as a safer alternative to barbiturates; along with newer benzodiazepines
More informationMs Anne Dowden. Independent Evaluation Consultant Wellington
Ms Anne Dowden Independent Evaluation Consultant Wellington 16:30-17:25 WS #66: Substance Impaired Driving: Patient Education 17:35-18:30 WS #78: Substance Impaired Driving: Patient Education (Repeated)
More informationINTRODUCTION. The drugs-and-driving problem
INTRODUCTION The drugs-and-driving problem Following nearly three decades of progress on the alcohol-crash problem, safety advocates, policy-makers, legislators and enforcement agencies have begun to express
More informationInsomnia Agents (Sherwood Employer Group)
Insomnia Agents (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf Link to
More informationIncreased criminal activity among people suspected of driving under the influence of alcohol or drugs. A register-based population-level study.
Increased criminal activity among people suspected of driving under the influence of alcohol or drugs. A. Abstract Dr. Antti Impinen, Dr. Pirjo Lillsunde National Institute for Health and Welfare, Injury
More informationEffects of Narcotic Analgesics on Driving
Effects of Narcotic Analgesics on Driving What is the Drug-Impaired Driving Learning Centre (DIDLC)? The Drug Impaired Driving Learning Centre (DIDLC) is a fully bilingual, web-based educational resource
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE
More informationOutline. Disclosure. Sleep and the Elderly 1,2. Background
Geriatric Grand Rounds Tuesday, March 31, 29 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationDo non-benzodiazepine-hypnotics prove a valuable alternative to benzodiazepines for the treatment of insomnia?
Do non-benzodiazepine-hypnotics prove a valuable alternative to benzodiazepines for the treatment of insomnia? A. KNUISTINGH NEVEN, DEPARTMENT OF GENERAL PRACTICE, LEIDEN UNIVERSITY MEDICAL CENTER Introduction
More informationThese slides are the intellectual property of Dr Hugh Selsick and must not be reproduced
AIMS - SAFETY BE AWARE OF THE CONTROVERSY AROUND: WHETHER HYPNOTICS INCREASE MORTALITY. WHETHER HYPNOTICS INCREASE FALLS. WHETHER THEY ARE ADDICTIVE. UNDERSTAND WHICH HYPNOTICS MAY INCREASE THE RISKS OF
More informationInteractions between Alcohol, Cannabis and Cocaine in Risks of Traffic Violations and Traffic Crashes
Interactions between Alcohol, Cannabis and Cocaine in Risks of Traffic Violations and Traffic Crashes 1 M.Chipman, 2 S. Macdonald and 3 R. Mann 1 Department of Public Health Sciences, University of Toronto,
More informationFriend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding
More informationMIDAZOLAM AND OXAZEPAM IN THE TREATMENT OF INSOMNIA IN HOSPITALIZED PATIENTS
Br. J. clin. Pharmac. (1983), 16, 145S-149S MIDAZOLAM AND OXAZEPAM IN THE TREATMENT OF INSOMNIA IN HOSPITALIZED PATIENTS 'Clinique des Maladies Infectieuses, H6pital Houphouet Boigny, Marseilles, France
More informationCannabis and the Risk of Crash Involvement
Cannabis and the Risk of Crash Involvement Matthew Baldock Drugs have long been a focus of law enforcement in Australia but recent legislation in a number of Australian states now requires routine drug
More informationDriving Under the Influence of Non-Alcohol Drugs An Update. Part II: Experimental Studies
Driving Under the Influence of Non-Alcohol Drugs An Update. Part II: Experimental Studies M. C. Strand*, H. Gjerde, J. Mørland Domain for Forensic Sciences Norwegian Institute of Public Health Oslo Norway
More informationIMMEDIATE AND RESIDUAL EFFECTS IN MAN OF THE METABOLITES OF DIAZEPAM
Br. J. clin. Pharmac. (1978), 6, 2-1 IMMEDIATE AND RESIDUAL EETS IN MAN O THE METABOLITES O DIAZEPAM ORAL H. LARKE & A.N. NIHOLSON Royal Air orce Institute of Aviation Medicine, arnborough, Hampshire I
More informationBritish Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology Br J Clin Pharmacol (2016) 82 1625 1635 1625 PHARMACOEPIDEMIOLOGY Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation
More informationComparison of driving performance in treated and untreated Obstructive Sleep Apnoea Syndrome (OSAS) patients and healthy controls
Comparison of driving performance in treated and untreated Obstructive Sleep Apnoea Syndrome (OSAS) patients and healthy controls Dr. Evangelos Bekiaris, Katerina Touliou, Dr. Maria Panou Centre for Research
More informationCANADIAN TRENDS IN BENZODIAZEPINE & ZOPICLONE USE
CANADIAN TRENDS IN BENZODIAZEPINE & ZOPICLONE USE Aliya Kassam 1, Scott B Patten 2 1 Institute of Psychiatry, London, UK, 2 Department of Community Health Sciences, University of Calgary, Calgary, Alberta,
More informationA Method to Assess the Dissipation of the Residual Effects of Hypnotics: Eszopiclone versus Zopiclone.
A Method to Assess the Dissipation of the Residual Effects of Hypnotics: Eszopiclone versus Zopiclone. Julia Boyle (PhD), 1 John A. Groeger (PhD), 2,3 Walter Paska (PhD), 4 James A. Cooper (PhD), 5 Carol
More informationEarlier arrests among apprehended drivers in Norway with heroin and ecstasy detection
Earlier arrests among apprehended drivers in Norway with heroin and ecstasy detection A. S. Christophersen¹, A. M. Hausken¹ and S. Skurtveit¹ ² ¹National Institute of Forensic Toxicology, P.O. Box 495
More informationCHOOSING WISELY TO IMPROVE CARE FOR GERIATRIC PATIENTS
CHOOSING WISELY TO IMPROVE CARE FOR GERIATRIC PATIENTS About Choosing Wisely First conceived by the National Physicians Alliance Funded by an ABIM Foundation grant Created 3 lists of steps physicians could
More informationDrug use and the severity of a traffic accident
Accident Analysis and Prevention 37 (2005) 427 433 Drug use and the severity of a traffic accident B.E. Smink a,, B. Ruiter a, K.J. Lusthof a, J.J. de Gier c,d, D.R.A. Uges b, A.C.G. Egberts d a Netherlands
More informationThe prevalence and impairment effects of drugged driving in New Zealand June 2017
The prevalence and impairment effects of drugged driving in New Zealand June 2017 Nicola J Starkey and Samuel G Charlton School of Psychology University of Waikato, Hamilton NZ Transport Agency research
More informationThe British Columbia Coroners Service is committed to conducting a thorough, independent examination of the factors contributing to death in order to
The British Columbia Coroners Service is committed to conducting a thorough, independent examination of the factors contributing to death in order to improve community safety and quality of life in the
More informationThe Road Safety Monitor. Drugs and Driving
The Road Safety Monitor Drugs and Driving The Traffic Injury The mission of the Traffic Injury (TIRF) is to reduce traffic-related deaths and injuries. TIRF is a national, independent, charitable road
More informationAlcohol and other drug involvement in fatally injured drivers in the United States
Alcohol and other drug involvement in fatally injured drivers in the United States James C. Fell and Eduardo Romano Pacific Institute for Research and Evaluation, Calverton, Maryland, USA Abstract Since
More informationHIGHway to Hell: The Science Behind Drugged Driving
HIGHway to Hell: The Science Behind Drugged Driving Facilitator: Brian Ursino, Director, Law Enforcement, AAMVA Presenters: John Lacey, Center Director, Pacific Institute for Research and Evaluation Mike
More informationThe Effects of Clobazam Upon Critical Flicker Fusion Thresholds: A Review
Drug Development Research Supplement 157-66 (1982) The Effects of Clobazam Upon Critical Flicker Fusion Thresholds: A Review A.C. Parrott Department of Psychology, University of Leeds, Leeds, England ABSTRACT
More informationAsian Journal of Phytomedicine and Clinical Research Journal home page:
Research Article CODEN: AJPCFF ISSN: 2321 0915 Asian Journal of Phytomedicine and Clinical Research Journal home page: www.ajpcrjournal.com STUDY OF ADR OF BENZODIAZEPINE S AT A PRIVATE CORPORATE HOSPITAL
More informationDrug-Impaired Driving in Europe
Drug-Impaired Driving in Europe What is the Drug-Impaired Driving Learning Centre (DIDLC)? The Drug Impaired Driving Learning Centre (DIDLC) is a fully bilingual, web-based educational resource that was
More informationSouth Australian Alcohol and Other Drug Strategy
South Australian Alcohol and Other Drug Strategy 2017-2021 September 2016 Contents Contents... 2 EXECUTIVE SUMMARY... 3 RECOMMENDATION... 3 DISCUSSION... 4 Background/Overview... 4 Key Information to Note...
More informationMMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA
MMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA Page 1 of 11 Table of Contents Why we need this Guideline... 3 What the Policy is trying to do... 3 Which stakeholders have been
More informationComparison of the Minisim and Stisim Driving Simulators for the Detection of Impairment: An Alcohol Validation Study
University of Iowa Iowa Research Online Driving Assessment Conference 2013 Driving Assessment Conference Jun 18th, 12:00 AM Comparison of the Minisim and Stisim Driving Simulators for the Detection of
More informationACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can
More informationMental Disorders and Illicit Drug Use Expert Group
Global Burden of Disease Mental Disorders and Illicit Drug Use Expert Group Louisa Degenhardt, Bianca Calabria, Wayne Hall and Michael Lynskey Overview of injuries/diseases to be included in the comparative
More informationDrug-related deaths and deaths among drug users in Ireland figures from the National Drug-Related Deaths Index
Drug-related deaths and deaths among drug users in Ireland 21 figures from the National Drug-Related Deaths Index January 213 Summary of 21 results This update presents figures from the National Drug-Related
More informationDesigner drugs and road safety in Japan
TECHNICAL CONSULTATION ON DRUG USE AND ROAD SAFETY WHO/HQ, GENEVA, SWITZERLAND, SALLE C 17 18 DECEMBER 2014 Designer drugs and road safety in Japan Kazuko Okamura National Research Institute of Police
More informationTitle: The Combined Effects of Alcohol and Cannabis on Driving: Impact on Crash Risk. Author: Sacha Dubois Nadia Mullen Bruce Weaver Michel
Title: The Combined Effects of Alcohol and Cannabis on Driving: Impact on Crash Risk Author: Sacha Dubois Nadia Mullen Bruce Weaver Michel Bédard PII: S0379-0738(14)00535-0 DOI: http://dx.doi.org/doi:10.1016/j.forsciint.2014.12.018
More informationOn-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers
pii: sp-00782-14 http://dx.doi.org/10.5665/sleep.5168 MORNING DRIVING PERFORMANCE AFER BEDTIME USE OF SUVOREXANT On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg:
More informationIntroduction. The Netherlands:
MEDICINAL DRUGS AND DRIVING SAFETY: A GRADED-LEVEL SYSTEM FOR LABELING Hilka Wolshrijn, Johan J. De Gier, James F. O'Hanlon (Institute for Drugs, Safety and Behavior - University of Limburg) & Peter A.G.M.
More information4/27/2016. About CCSA. Impaired Driving Research at CCSA. Background. Presentation Overview. Lessons Learned
About CCSA Drug-Impaired Driving i in Canada: Lessons Learned International Conference on Urban Traffic Safety Amy Porath-Waller, Ph.D. April 26, 2016 CCSA is Canada s only agency with a legislated national
More informationDrug related hospital stays in Australia
Prepared by Funded by Amanda Roxburgh and Courtney Breen, National Drug and Alcohol Research Centre the Australian Government Department of Health Recommended Roxburgh, A. and Breen, C (217). Drug-related
More informationReduction in the Use of Night Sedation to Reduce the Risk of Falls
Reduction in the Use of Night Sedation to Reduce the Risk of Falls Ms Margaret Hargraves Hospital Pharmacist Prince of Wales Hospital South Eastern Sydney Illawarra Area Health Service Objectives Falls
More informationAlcohol and other drug use in New Zealand. drivers 2004 to 2009 EVALUATION OF THE AUROJECT
Alcohol and other drug use in New Zealand drivers 2004 to 2009 EVALUATION OF THE AUROJECT Alcohol and other drug use in New Zealand drivers 2004 to 2009 Prepared by Dr Helen Poulsen Environmental Science
More informationCozart DDS Drug Detection System On-site Saliva Drug Testing
Cozart DDS Drug Detection System On-site Saliva Drug Testing www.siemens.com Siemens Healthcare Diagnostics Drug Testing, under the Cozart brand name, has more than a 10-year legacy of providing an extensive
More informationResident Fatigue. A Primer For Residents
Resident Fatigue A Primer For Residents Andrew Martin, MD Chair, Pulmonary Department Deborah Heart and Lung Center Clinical Associate Professor of Medicine MartinA@Deborah.org June 2016 Pre-Test Questions
More informationDriving tests with patients
Br. J. clin. Pharmac. (1984), 18, 103S-108S Driving tests with patients J. J. de GIER Department of Pharmacotherapy, Subfaculty of Pharmacy, Drugs and Driving Research Group, State University of Utrecht,
More informationRandom drug testing in Australia, analogies with RBT, and likely effects with increased intensity levels
Random drug testing in Australia, analogies with RBT, and likely effects with increased intensity levels Professor Max Cameron Monash Injury Research Institute Australian research on drug driving risk
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20252 holds various files of this Leiden University dissertation. Author: Manthey, Leonie Title: Determinants and consequences of long-term benzodiazepine
More informationThe Worldwide Decline in Drinking and Driving
The Worldwide Decline in Drinking and Driving Barry M. Sweedler National Transportation Safety Board, 490 L Enfant Plaza, S.W., Washington, DC 20594 USA ABSTRACT At a session conducted at the Traffic Safety
More informationImplications of benzodiazepines in drug related deaths
Implications of benzodiazepines in drug related deaths Analyses of the french special mortality register data (DRAMES) Dr Michel Mallaret CEIP-Addictovigilance Grenoble France Lisboa, october 15th 2014
More informationExecutive Summary: Licit Schedule II Drug Use and Commercial Motor Vehicle Driver Safety. October 21, 2006
Executive Summary: Licit Schedule II Drug Use and Commercial Motor Vehicle Driver Safety Presented to Federal Motor Carrier Safety Administration October 21, 2006 Prepared for Prepared by MANILA Consulting
More informationPencil and paper tests- sensitivity to psychotropic drugs
Br. J. clin. Pharmac. (1984), 18, 15S-20S Pencil and paper tests- sensitivity to psychotropic drugs BARBARA M. STONE Royal Air Force Institute of Aviation Medicine, Farnborough, Hampshire 1 The literature
More informationTests performed study different parameters of vigilancy, and performances in real driving situation.
DOUBLE-BLIND STUDY OF THE EFFECTS OF A COMBINATION OF BROMAZEPAM-ALCOHOL VS PLACEBO-ALCOHOL IN 11 AUTOMOBILE DRIVERS 1) C. MERCIER-GUYON, Centre Midico-Sportif, ANNECY, F. 2) F. RICHET, L.A.R.C.C.A., BRETIGNY/ORGE,
More informationFindings of Drug Driving Expert Technical Panel
Findings of Drug Driving Expert Technical Panel Dr Kim Wolff Chair Reader in Addiction Science King s College London 1 Background: Government in its response to the North review indicated: Driving while
More informationA REVIEW BY PROFESSOR C HEATHER ASHTON, DM, FRCP
BENZODIAZEPINES; RISKS AND BENEFITS. A RECONSIDERATION Baldwin, Aitchison, Bateson, Curran, Davies, Leonard, Nutt, Stephens and Wilson. J Psychopharmacol 2013, 27 (11) 967-71 A REVIEW BY PROFESSOR C HEATHER
More informationADDRESSING THE PROBLEM OF MARIJUANA- IMPAIRED DRIVING By Teri Moore May 2018
Cannabis Policy Policy Cannabis Series ADDRESSING THE PROBLEM OF MARIJUANA- IMPAIRED DRIVING By Teri Moore May 2018 States that have decriminalized or plan to decriminalize marijuana use are grappling
More informationStandardized Field Sobriety Testing Refresher
Standardized Field Sobriety Testing Refresher Location Date Instructor needs to put in Location and Date. SESSION I: INTRODUCTION AND OVERVIEW Upon successfully completing this session, the participant
More informationDrug-related deaths and deaths among drug users in Ireland figures from the National Drug-Related Deaths Index
Drug-related deaths and deaths among drug users in Ireland 2011 figures from the National Drug-Related Deaths Index January 2014 Summary of 2011 results This update presents figures from the National Drug-Related
More informationEvaluating Drug Effects on the Ability to Operate a Motor Vehicle Guidance for Industry
Evaluating Drug Effects on the Ability to Operate a Motor Vehicle Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationANTEROGRADE AMNESIA INDUCED BY THE HYPNOTIC DIAZEPAM IS NOT ASSOCIATED WITH SLEEPINESS
ANTEROGRADE AMNESIA INDUCED BY THE HYPNOTIC DIAZEPAM IS NOT ASSOCIATED WITH SLEEPINESS Agnieszka Unrug l, Marielle Gorissen 2, Gilles van Luijtelaar l, Anton Coenen l 1 NICI, Department of Psychology,
More informationA study comparing the effectiveness of three warning labels on the package of driving-impairing medicines
Postprint Version Journal website Pubmed link DOI 1.0 http://link.springer.com/article/10.1007%2fs11096-014-0010-2 http://www.ncbi.nlm.nih.gov/pubmed/25204257 10.1007/s11096-014-0010-2 A study comparing
More informationYou May Be at Risk. You are taking one of the following sedative-hypnotic medications: Diazepam (Valium ) Estazolam. Flurazepam.
You May Be at Risk You are taking one of the following sedative-hypnotic medications: Alprazolam (Xanax ) Diazepam (Valium ) Temazepam (Restoril ) Chlorazepate Estazolam Triazolam (Halcion ) Chlordiazepoxide
More informationAlcohol consumption and traffic and non-traffic accidents in Australia,
Alcohol consumption and traffic and non-traffic accidents in Australia, 1924-26 Michael Livingston 1, 2 & Heng Jiang 1 1 Centre for Alcohol Policy Research, Turning Point Alcohol and Drug Centre, Melbourne,
More informationWHAT SHOULD WE DO ABOUT BENZODIAZEPINES? Miriam Komaromy, MD Associate Director, Project ECHO August 2014
WHAT SHOULD WE DO ABOUT BENZODIAZEPINES? Miriam Komaromy, MD Associate Director, Project ECHO August 2014 EPIDEMIOLOGY OF BENZO USE 7-18% of US population uses a benzo for medical purposes each year Average
More informationMarijuana Impaired Drivers in Montana
Marijuana Impaired Drivers in Montana Rebecca Sturdevant, MSN, APRN,BC, COHN-S, C-SAPA Rebecca Sturdevant, MSN RN 32 yr, APRN prescriptive authority 17 yr Lived on Mexican border, CA & TX, 20 yr Immigration
More information11/1/2010. Psychology 472 Pharmacology of Psychoactive Drugs. Listen to the audio lecture while viewing these slides
Treatment for Anxiety Disorders Benzodiazepines and Other Anxiolytics Psychology 472 Pharmacology of Psychoactive Drugs Listen to the audio lecture while viewing these slides Ethanol Barbiturates and related
More informationNOT FOR HUMAN CONSUMPTION
HARMFUL NOT FOR PRESENTATION TO ANYONE UNDER 18 NOT FOR HUMAN CONSUMPTION Benzodiazepines Diazepam Estazolam Etizolam Flunitrazepam Clorazepate Flutoprazepam Phenazepam Tetrazepam Nimetazepam Nordazepam
More informationCANADIAN CANNABIS CRAZE (AND CONUNDRUM) Dr. Melissa Snider-Adler Chief Medical Review Officer DriverCheck Inc. Addiction Medicine Physician
CANADIAN CANNABIS CRAZE (AND CONUNDRUM) Dr. Melissa Snider-Adler Chief Medical Review Officer DriverCheck Inc. Addiction Medicine Physician AGENDA THC IMPAIRMENT A deep dive into THC vs. CBD Signs and
More informationFatal traffic accidents in which no alcohol is detected: Are drugs related?
T2007 Seattle, Washington Fatal traffic accidents in which no alcohol is detected: Are drugs related? Rosario García-Repetto *, Mª Luisa Soria, Mª Paz Giménez and Carmen Jurado. National Institute of Toxicology
More informationMedical Marijuana. Implications for Driving and the Workplace
Medical Marijuana. Implications for Driving and the Workplace Dr William Isles MBBS MPH FAFOEM www.racpcongress.com.au Medical Cannabis Driving and Occupation MJA article: Compassion and evidence in prescribing
More informationScottish Blues- Benzodiazepines and Drug Related Deaths in Scotland
Scottish Blues- Benzodiazepines and Drug Related Deaths in Scotland EMCDDA Sep. 25 th 2014 Dr Saket Priyadarshi Associate Medical Director NHS Greater Glasgow and Clyde Vice-Chair, National Forum on Drug
More information